Fig. 7

Combination of glimepiride with IR improves survival of GBM-bearing mice. A A schematic diagram of control, IR (2 Gy × 5), IR with glimepiride (5 mg/kg, oral), and IR with temozolomide (20 mg/kg, i.p.) treatment in mice bearing U87MG-luciferase xenografts (n = 20 mice per group). B In vivo bioluminescent images of orthotopic xenografts derived from U87MG-luciferase in mice control, treated with IR, IR with glimepiride, or IR with temozolomide. C Survival analysis by Kaplan-Meier curves and log-rank (Mantel-Cox) test of mice bearing U87MG-luciferase xenografts control, treated with IR, IR with glimepiride, or IR with temozolomide. D Hematoxylin and eosin (H&E) staining (upper panel) and immunohistochemistry (anti-Spy1 and anti-CLIP3; middle and lower panel) of coronal sections from mice bearing U87MG-luciferase xenografts control, treated with IR, or IR with glimepiride. Scale bars, 2000 μm (upper) or 50 μm (lower). E Schematic diagram depicting that CLIP3 activation by glimepiride impairs radioresistance of GSCs